Literature DB >> 12620508

R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model.

Connie Sánchez1.   

Abstract

Escitalopram mediates the serotonin reuptake inhibitory effect of citalopram. To investigate the potential interactive effects between escitalopram and R-citalopram, they were studied at standard and elevated serotonin levels in a model predictive of anxiolytic activity (inhibition of footshock-induced ultrasonic vocalisation in adult rats). At standard levels, citalopram partially inhibited (64%) and escitalopram abolished (97%) vocalisation. Co-treatment with L-5-hydroxytryptophan resulted in complete inhibition with citalopram and a substantially enhanced response to escitalopram, while R-citalopram increased the vocalisation significantly. Furthermore, R-citalopram attenuated the effect of escitalopram. These findings may be relevant to the enhanced clinical efficacy seen with escitalopram compared to citalopram.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620508     DOI: 10.1016/s0014-2999(03)01376-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Changes in behavior and ultrasonic vocalizations during antidepressant treatment in the maternally separated Wistar-Kyoto rat model of depression.

Authors:  P J van Zyl; J J Dimatelis; V A Russell
Journal:  Metab Brain Dis       Date:  2013-12-12       Impact factor: 3.584

2.  Specific effects of escitalopram on neuroendocrine response.

Authors:  Emily R Hawken; James A Owen; Robert W Hudson; Nicholas J Delva
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

Review 3.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

4.  Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.

Authors:  J C Winter; J R Eckler; K C Rice; R A Rabin
Journal:  Pharmacol Biochem Behav       Date:  2005-07       Impact factor: 3.533

5.  Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.

Authors:  Georg Nikisch; Aleksander A Mathé; Adelheid Czernik; Jutta Thiele; Jürgen Bohner; Chin B Eap; Hans Agren; Pierre Baumann
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

6.  Changes in antidepressant metabolism and dosing across pregnancy and early postpartum.

Authors:  Dorothy K Sit; James M Perel; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychiatry       Date:  2008-04       Impact factor: 4.384

7.  R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter.

Authors:  Signe í Stórustovu; Connie Sánchez; Peter Pörzgen; Lise T Brennum; Anna Kirstine Larsen; Monica Pulis; Bjarke Ebert
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

Review 8.  Escitalopram versus citalopram: the surprising role of the R-enantiomer.

Authors:  Connie Sánchez; Klaus P Bøgesø; Bjarke Ebert; Elin Heldbo Reines; Claus Braestrup
Journal:  Psychopharmacology (Berl)       Date:  2004-07       Impact factor: 4.530

Review 9.  Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.

Authors:  Brian Leonard; David Taylor
Journal:  J Psychopharmacol       Date:  2010-02-10       Impact factor: 4.153

10.  Validated Densitometric TLC-Method for the Simultaneous Analysis of (R)- and (S)-Citalopram and its Related Substances Using Macrocyclic Antibiotic as a Chiral Selector: Application to the Determination of Enantiomeric Purity of Escitalopram.

Authors:  Suzan Mahmoud Soliman
Journal:  Int J Biomed Sci       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.